Keyphrases
Arthritis
6%
Arthritis Patients
9%
Biologic Disease-modifying Antirheumatic Drugs
6%
Calcinosis
12%
Childhood Arthritis
96%
Childhood-onset Systemic Lupus Erythematosus
15%
Clinical Characteristics
12%
Clinical Outcomes
5%
Confidence Interval
5%
Consensus Treatment Plans
21%
Corticosteroids
5%
Disease Activity
14%
Disease Outcome
6%
Disease-modifying Antirheumatic Drugs (DMARDs)
9%
Etanercept
5%
First Year
5%
Functional Disability
9%
Inactive Disease
8%
Juvenile Arthritis Disease Activity Score
5%
Juvenile Dermatomyositis
23%
Lupus
9%
Lupus Nephritis
13%
Medication Use
5%
Methotrexate
5%
Newly Diagnosed
5%
Patient Characteristics
5%
Patient-reported Outcomes
11%
Patient-Reported Outcomes Measurement Information System (PROMIS)
8%
Pediatric
5%
Pediatric Lupus
5%
Pediatric Rheumatology
9%
Race-ethnicity
5%
Rash
6%
Registry Study
5%
Research Partnerships
96%
Rheumatic Diseases
12%
Rheumatic Manifestations
8%
Rheumatoid Factor
5%
Rheumatologists
5%
Rheumatology
8%
Rheumatology Research
96%
Serious Adverse Events
6%
Systemic Juvenile Idiopathic Arthritis (sJIA)
88%
Systemic Lupus Erythematosus
11%
Medicine and Dentistry
Arthritis
94%
Biological Product
20%
Calciphylaxis
11%
Cohort Analysis
5%
Disease Activity
21%
Disease Course
6%
Disease Modifying Antirheumatic Drug
13%
Diseases
39%
Effectiveness Study
5%
Etanercept
5%
Exanthem
5%
Glucocorticoid
10%
Interleukin 1
5%
Interleukin 6
5%
Juvenile Dermatomyositis
18%
Juvenile Idiopathic Arthritis
55%
Lupus Erythematosus
9%
Lupus Nephritis
13%
Methotrexate
10%
Observational Study
10%
Outcome Assessment
5%
Patient-Reported Outcome
15%
Pediatric Rheumatology
12%
Pediatrics
14%
Quality of Life
7%
Rheumatic Disease
13%
Rheumatology
100%
Social Determinants of Health
5%
Systemic Juvenile Idiopathic Arthritis
18%
Systemic Lupus Erythematosus
24%
TNF Inhibitor
5%
